Abstract: The present invention relates to an aqueous pharmaceutical composition for parenteral administration to a human, comprising a pharmacologically effective amount of a pharmaceutically acceptable vitamin K, a polyethoxylated castor oil as solubilizer, and a citrate buffer at a concentration of 1 to 40 mmol/L, wherein the pH of the composition is between 3.5 and 7.0, to a pharmaceutically acceptable container comprising the composition, and to the composition for use in the treatment or prevention of vitamin K deficiency and/or haemorrhage or for use as an antidote to anticoagulants of the coumarin type as well as to a method for preparing the composition.

Abstract: The present invention relates to a semi-solid filling medium which comprises a camptothecin derivative; a pharmaceutically acceptable carrier matrix which is a polyglycolized glyceride; and an effective thickening-reducing and stabilizing-promoting amount of one or more pharmaceutically acceptable excipients.

Abstract: A pharmaceutical formulation which comprises a parenterally acceptable carrier or diluent, estramustine phosphate and a sulfoalkyl ether cyclodextrin. The formulation can be administered according to a combined chemotherapy regimen in association with one or more chemotherapeutic agents. The formulation also enables estramustin phosphate to be administered with no side effects at the site of injection.

Abstract: The present invention concerns the use of aromatase inhibitor exemestane, either alone or in combination with other therapeutic agents in the chemoprevention of estrogen dependent cancer in mammals, including humans, at increased risk of the disease.

Abstract: The present invention relates to the use of arginine and, more in particular, to the injectable formulations for intravenous use comprising it, in the prevention and treatment of the side effects associated with the extravasation of drugs administered by intravenous route.

Abstract: An oral pharmaceutical formulation, which comprises, in a hydroxypropylmethylcellulose capsule, a camptothecin analogue dispersed or solubilized in a semi-solid matrix of a polyethyleneglycol with a molecular weight ranging from 400 to 20000.

Abstract: The present invention relates to bioadhesive starches, to a process for their preparation and to pharmaceutical compositions containing them. It also relates to the use of such bioadhesive starches as carriers for the administration of a drug.

Abstract: The present invention provides a pharmaceutical composition comprising an estramustine derivative and a cyclodextrin, particularly in the manufacture of a medicament suitable for the oral administration of an estramustine derivative to a patient suffering from a tumor.Estramustine derivatives according to the invention are, for example, compounds of general formula (I) ##STR1## wherein R is ##STR2## in which R.sub.1 is C.sub.1 -C.sub.4 alkyl and n is 0, 1 or 2, and the pharmaceutically acceptable salts thereof.